FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385856771> ?p ?o ?g. }

• W4385856771 endingPage "e30708e8" @default.
• W4385856771 startingPage "e30708e8" @default.
• W4385856771 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Patients with multiple myeloma (MM) and high-risk (HR) cytogenetic abnormalities have inferior outcomes, and are under-represented in clinical trials. There is paucity of data regarding outcomes of MM patients with multiple HR abnormalities undergoing autologous stem cell transplant (autoSCT). Aims: To evaluate outcomes of autoSCT in patients with newly diagnosed MM and two or more HR abnormalities. Methods: We conducted a retrospective, single-center analysis of adult HRMM patients that received autoSCT between 2008-2018. HR cytogenetics were defined as del17p, t(4;14), t(14;16), 1q21 gain or amplification (1q+) by fluorescence in situ hybridization. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Associations between OS and PFS and measures of interest were determined using Cox proportional hazards regression models. Measures that occur after autoSCT were included in the regression models as time-dependent covariates. Results: Seventy-nine patients with HRMM were included in our analysis, with a median age of 61 (range 33.5-76.5) years and 57% were female. Sixty-seven patients had two HR cytogenetic abnormalities, while 12 had three abnormalities. The most common combinations of HR abnormalities were [1q+, t(4:14)] (n=25, 32%) and [1q+, del 17p] (n=21, 27%). The most common induction regimens used were VRD (48%) and KRD (16%). Prior to autoSCT, 52 patients (66%) achieved ≥VGPR, while 23 patients (29%) achieved MRD negative ≥VGPR pre-transplant. Fifty-six (71%) patients received post-transplant maintenance therapy (Table 1). At day 100 post autoSCT and at best post-transplant responses, 36 patients (46%) and 40 patients (51%) achieved MRD negative ≥VGPR, respectively. With a median follow-up in surviving patients of 38.3 (range: 11.9 to 104.8) months, the median PFS and OS in the entire cohort were 22.9 and 71.5 months, respectively (Figure 1). For the subset of patients with three HR abnormalities, the median PFS was 15.6 months and median OS was 28.0 months. Achieving MRD negative ≥VGPR either prior to autoSCT (hazard ratio 0.35; p=0.007) or at best response after autoSCT (HR 0.50; p=0.037), were associated with improved PFS in univariate analysis (UVA), but not in multivariable analysis (MVA). In UVA for OS, male gender (HR 0.37; p=0.025), younger age (HR 0.48, p: 0.012), presence of 1q+ (HR 0.43; p=0.045) and achieving MRD negative ≥VGPR post autoSCT (HR 0.30; p=0.010) were associated with significantly better OS. On MVA, only male gender (HR 0.31; p=0.030) and achieving MRD negative ≥VGPR post autoSCT (HR 0.30; p=0.034) remained significant. Summary/Conclusion: MM patients with ≥ 2 HR abnormalities have a median PFS of <24 months with the current standard of care, and may require novel treatment modalities, including CAR-T and bispecific antibodies, earlier in their disease course.Keywords: Cytogenetic abnormalities, High risk, Multiple myeloma, Autologous hematopoietic stem cell transplantation" @default.
• W4385856771 created "2023-08-17" @default.
• W4385856771 creator A5008785159 @default.
• W4385856771 creator A5015342719 @default.
• W4385856771 creator A5020558212 @default.
• W4385856771 creator A5022871468 @default.
• W4385856771 creator A5029237145 @default.
• W4385856771 creator A5037077714 @default.
• W4385856771 creator A5037963602 @default.
• W4385856771 creator A5038186608 @default.
• W4385856771 creator A5038235561 @default.
• W4385856771 creator A5038619722 @default.
• W4385856771 creator A5048362577 @default.
• W4385856771 creator A5048913229 @default.
• W4385856771 creator A5055885795 @default.
• W4385856771 creator A5055929208 @default.
• W4385856771 creator A5060313982 @default.
• W4385856771 creator A5068834306 @default.
• W4385856771 creator A5069460930 @default.
• W4385856771 creator A5069676375 @default.
• W4385856771 creator A5071516639 @default.
• W4385856771 date "2023-08-01" @default.
• W4385856771 modified "2023-09-23" @default.
• W4385856771 title "P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES" @default.
• W4385856771 doi "https://doi.org/10.1097/01.hs9.0000972004.30708.e8" @default.
• W4385856771 hasPublicationYear "2023" @default.
• W4385856771 type Work @default.
• W4385856771 citedByCount "0" @default.
• W4385856771 crossrefType "journal-article" @default.
• W4385856771 hasAuthorship W4385856771A5008785159 @default.
• W4385856771 hasAuthorship W4385856771A5015342719 @default.
• W4385856771 hasAuthorship W4385856771A5020558212 @default.
• W4385856771 hasAuthorship W4385856771A5022871468 @default.
• W4385856771 hasAuthorship W4385856771A5029237145 @default.
• W4385856771 hasAuthorship W4385856771A5037077714 @default.
• W4385856771 hasAuthorship W4385856771A5037963602 @default.
• W4385856771 hasAuthorship W4385856771A5038186608 @default.
• W4385856771 hasAuthorship W4385856771A5038235561 @default.
• W4385856771 hasAuthorship W4385856771A5038619722 @default.
• W4385856771 hasAuthorship W4385856771A5048362577 @default.
• W4385856771 hasAuthorship W4385856771A5048913229 @default.
• W4385856771 hasAuthorship W4385856771A5055885795 @default.
• W4385856771 hasAuthorship W4385856771A5055929208 @default.
• W4385856771 hasAuthorship W4385856771A5060313982 @default.
• W4385856771 hasAuthorship W4385856771A5068834306 @default.
• W4385856771 hasAuthorship W4385856771A5069460930 @default.
• W4385856771 hasAuthorship W4385856771A5069676375 @default.
• W4385856771 hasAuthorship W4385856771A5071516639 @default.
• W4385856771 hasBestOaLocation W43858567711 @default.
• W4385856771 hasConcept C126322002 @default.
• W4385856771 hasConcept C141071460 @default.
• W4385856771 hasConcept C143998085 @default.
• W4385856771 hasConcept C2776364478 @default.
• W4385856771 hasConcept C2779050716 @default.
• W4385856771 hasConcept C2780073493 @default.
• W4385856771 hasConcept C2911091166 @default.
• W4385856771 hasConcept C50382708 @default.
• W4385856771 hasConcept C71924100 @default.
• W4385856771 hasConceptScore W4385856771C126322002 @default.
• W4385856771 hasConceptScore W4385856771C141071460 @default.
• W4385856771 hasConceptScore W4385856771C143998085 @default.
• W4385856771 hasConceptScore W4385856771C2776364478 @default.
• W4385856771 hasConceptScore W4385856771C2779050716 @default.
• W4385856771 hasConceptScore W4385856771C2780073493 @default.
• W4385856771 hasConceptScore W4385856771C2911091166 @default.
• W4385856771 hasConceptScore W4385856771C50382708 @default.
• W4385856771 hasConceptScore W4385856771C71924100 @default.
• W4385856771 hasIssue "S3" @default.
• W4385856771 hasLocation W43858567711 @default.
• W4385856771 hasLocation W43858567712 @default.
• W4385856771 hasOpenAccess W4385856771 @default.
• W4385856771 hasPrimaryLocation W43858567711 @default.
• W4385856771 hasRelatedWork W1818467446 @default.
• W4385856771 hasRelatedWork W1969994327 @default.
• W4385856771 hasRelatedWork W2043667488 @default.
• W4385856771 hasRelatedWork W2233317116 @default.
• W4385856771 hasRelatedWork W2582431155 @default.
• W4385856771 hasRelatedWork W3004485101 @default.
• W4385856771 hasRelatedWork W3094273986 @default.
• W4385856771 hasRelatedWork W3128298999 @default.
• W4385856771 hasRelatedWork W4242486230 @default.
• W4385856771 hasRelatedWork W3111377176 @default.
• W4385856771 hasVolume "7" @default.
• W4385856771 isParatext "false" @default.
• W4385856771 isRetracted "false" @default.
• W4385856771 workType "article" @default.